Clinical Trials Browser

Phase 1/2 × Brentuximab Vedotin × Other hematologic neoplasm × Clear all

NCT02096042 2023-10-10

Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

Phase 1/2 Terminated

1 enrolled 3 charts

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT01620229 2014-04-21

Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Phase 1/2 Withdrawn

Other hematologic neoplasm

Hematologic Neoplasms